

1 **Quantitative analysis of active pharmaceutical ingredients (APIs)** 2 **using a potentiometric electronic tongue in a SIA flow system**

3
4 M. Wesoly¹, X. Cetó², M. del Valle², P. Ciosek¹, W. Wróblewski^{*1}

5
6 ¹*Department of Microbioanalytics, Faculty of Chemistry, Warsaw University of*
7 *Technology, Noakowskiego 3, 00-664 Warsaw, Poland*

8 ²*Sensors and Biosensors Group, Department of Chemistry, Universitat Autònoma de*
9 *Barcelona, Edifici Cn, 08193 Bellaterra, Barcelona, Spain*

10
11 *Corresponding author:

12 Tel/fax.: +48 22 2345631, e-mail address: wuwu@ch.pw.edu.pl

13 14 **Abstract**

15 An advanced potentiometric electronic tongue and Sequential Injection Analysis (SIA)
16 measurement system was applied for the quantitative analysis of mixtures containing
17 three active pharmaceutical ingredients (APIs): acetaminophen, ascorbic acid and
18 acetylsalicylic acid, in the presence of various amounts of caffeine as interferent. The
19 flow-through sensor array was composed of miniaturized classical ion-selective
20 electrodes based on plasticized PVC membranes containing only ion exchangers.
21 Partial Least Squares (PLS) analysis of the steady-state sensor array responses,
22 measured in API mixtures prepared by the SIA system permitted a correct
23 quantitative analysis of acetylsalicylic acid and ascorbic acid. Further optimization
24 using multiway PLS fed by dynamic responses without additional feature extraction
25 did not improve significantly the resolution of acetaminophen. Lastly, the
26 chemometric treatment, involving the extraction of dynamic components of the
27 transient response employing the Wavelet transform, the removal of less-significant
28 coefficients by means of Causal Index pruning and training of an Artificial Neural
29 Network (ANN) with the selected coefficients, allowed the simultaneous
30 determination of all the three studied APIs, while counterbalancing any interference
31 due to caffeine.

32
33 **Keywords:** pharmaceutical analysis; active pharmaceutical ingredients (APIs); ion-
34 selective electrodes; automated electronic tongue; sequential injection analysis

35

36 1. Introduction

37

38 Multidrug pharmaceutical preparations containing paracetamol and non-steroidal
39 anti-inflammatory drugs (NSAID) such as acetylsalicylic acid or ibuprofen are
40 commonly used for the flu treatment and flu-like illnesses. Frequently, they are
41 combined with antihistamines e.g. diphenhydramine and pheniramine maleate and
42 other active pharmaceutical ingredients (APIs) as caffeine, codeine, derivatives of
43 pyrazolones, barbiturates. Paracetamol and NSAIDs are applied for treatment of mild
44 to moderate pain and fever, while the antihistamines prevent many of the symptoms
45 of an allergic reaction like nasal congestion. Addition of codeine or caffeine improves
46 the pharmacological efficiency of paracetamol and NSAIDs. Moreover, the multidrug
47 formulations are less harmful to the main metabolic organs, because smaller amount
48 of each component are introduced in comparison with monocomponent drug [1,2].

49 Since analgesic drugs as acetylsalicylic acid, ibuprofen or paracetamol are generally
50 available over the counter (OTC) they are daily used by millions of people for
51 household relief of pain and thus accidental and deliberate overdose are common.
52 Paracetamol is a tolerable drug in standard dose, while NSAIDs often cause gastro-
53 toxicity which is depended on dose and product. High risk of gastrointestinal bleeding
54 is especially associated with taking even low-dose of aspirin, whereas ibuprofen
55 seems to carry lower risk of gastro-toxicity. Regarding the extended use of such
56 formulations, the development of analytical methods for the quality assessment of
57 these products is needed [3,4].

58 The analysis of pharmaceuticals involves pre-clinical and early phase clinical studies
59 of a candidate for a new drug as well as routine analysis during production.
60 Preclinical studies include the characterisation of a drug, identification of the effective
61 dose and range and the tissues in which side effects may occur. During clinical trials,
62 high-performance liquid chromatography (HPLC), UV-Vis spectrophotometry and
63 potentiometric titration are useful to characterize drugs in 0 (preclinical) and I phase
64 of clinical trials [5]. Moreover, several methods of API analysis in pure form, mixtures
65 and commercial products have been reported. HPLC is the most common technique
66 used for targeted NSAID analysis, especially coupled with MS detection employing
67 different ionization systems [6,7]. As an example, HPLC with optical detection was
68 applied for the determination of active pharmaceutical ingredients: paracetamol,
69 acetylsalicylic acid, caffeine in pharmaceutical preparations [1,2,8,9]. Conventional
70 and derivative spectrophotometry, often combined with chemometric procedures, was

71 also proposed for the multi- component analysis of drugs [10-14]. Voltammetric
72 measurements at modified or unmodified electrodes enabled the resolution of various
73 pharmaceutical compounds [15-18].

74 On the other hand, portable and compact electrochemical sensors, providing fast
75 measurements with high selectivity and sensitivity, could be competitive to classical
76 instrumental techniques dedicated for the analysis of pharmaceuticals. Among them,
77 potentiometric sensors – ion-selective electrodes (ISEs) – are the most promising for
78 such purpose [19,20]. ISEs based on polymer membranes doped with the ion-pair
79 complex of tetraoctylammonium cation were developed for the analysis of ibuprofen
80 [21,22]. Similar approach was proposed for the design of ion-selective electrodes
81 sensitive towards: naproxen [23], ketoprofen [24] and caffeine [25]. It is worth to note,
82 that the use of potentiometric sensors provided measurements in flow injection mode
83 (see a review on the application of Flow Injection Analysis (FIA) and Sequential
84 Injection Analysis (SIA) for pharmaceutical analysis in [26]).

85 Recently, electronic tongue (e-tongue) systems composed of sensor arrays and
86 pattern recognition tools were tested in pharmaceutical applications [27-29]. Since
87 the majority of commonly used active pharmaceutical ingredients have a bitter taste,
88 various methods for taste masking were developed and the e-tongue devices were
89 exploited for the evaluation of the efficiency of such methods. An array of classical or
90 miniaturized ISEs was proposed for the assessment of taste masking effect of
91 selected pharmaceuticals modified with co-spray excipients (microencapsulation
92 method) [29,30]. Potentiometric multisensor systems were employed for the
93 quantification of the bitter taste of diverse active pharmaceutical ingredients [31,32].
94 Finally, the performances of commercial e-tongues dedicated to the analysis of
95 pharmaceutical formulations were also compared [27,33,34].

96 In this work, an automated method for the quantitative analysis of selected active
97 pharmaceutical ingredients (acetaminophen, ascorbic acid, and acetylsalicylic acid)
98 involving an array of miniaturized potentiometric electrodes based on well-known
99 lipophilic salts (ion-exchangers) was reported. Calibration and measurement with the
100 electrode array was implemented with the aid of sequential injection analysis (SIA)
101 system. Among different measurement conditions and data treatment, incorporation
102 of dynamic components of the transient response is reported as the means to
103 improve modeling capability and resolution.

104

105

106 2. Experimental

107

108 2.1. Chemicals and membrane materials

109

110 The active pharmaceutical ingredients (APIs): acetaminophen $pK_a=9.50$
111 (paracetamol, PARA), ascorbic acid $pK_a=4.17$ (ASC), acetylsalicylic acid $pK_a=3.50$
112 (ASA) were purchased from Sigma-Aldrich, whereas hydrochloric acid, lithium
113 acetate, tris(hydroxymethyl)aminomethane (TRIS) and caffeine $pK_a=0.70$ (KOF) of
114 analytical grade were purchased from Fluka. The solutions of APIs (0.04 mol/L
115 acetaminophen, 0.014 mol/L ascorbic acid, 0.016 mol/L acetylsalicylic acid), caffeine
116 (2.6 mmol/L), lithium acetate (1 mmol/L), TRIS buffer solution (1 mmol/L) were
117 prepared with deionised water. The pH of solutions was adjusted by the addition of
118 hydrochloric acid or sodium hydroxide solution. High-molecular-weight poly(vinyl
119 chloride) (PVC), plasticizers: o-nitrophenyl octyl ether (o-NPOE), bis(2-ethylhexyl)
120 sebacate (DOS), lipophilic salts: potassium tetrakis [3,5-bis(trifluoromethyl)phenyl]
121 borate (KTFPB), tridodecylmethylammonium chloride (TDMAC),
122 tributylhexadecylphosphonium bromide (TBHDPB) and ionic liquid 1-decyl-3-
123 methylimidazolium chloride (IL) were obtained from Fluka. Freshly distilled
124 tetrahydrofuran (Fluka) was used as a solvent for the membrane components.

125

126 2.2. Sensor array

127

128 The flow-through sensor array consisted of 8 miniaturized electrodes based on PVC
129 membranes (plasticized using DOS or o-NPOE), containing an appropriate lipophilic
130 salt, exhibiting generic anion (TDMAC, TBHDPB, IL) or cation (KTFBB) response.
131 Two electrode specimens were prepared for each membrane composition. The
132 method of membranes preparation and electrodes conditioning were the same as for
133 the standard ISEs. The membranes contained: 1-3.5 wt% lipophilic salt, 64-66 wt%
134 plasticizer, 32-33 wt% high-molecular-weight PVC (see Table 1). The membrane
135 components (200 mg in total) were dissolved in 2 mL of THF. A detailed architecture
136 of the miniaturized ion-selective electrodes compatible with a single flow-through
137 module was presented in [35], whereas the design of the modular flow-cell system is
138 a subject of a polish patent application [36]. NaCl solution (0.01 mol/L) was used as
139 an internal filling. The constructed sensors were preconditioned overnight in a dilute
140 solution of internal electrolyte for at least 24 hours.

141 2.3. Instrumentation and EMF measurements

142

143 All measurements were carried out in flow-through mode with cells of the following
144 type: Ag, AgCl; KCl 3 mol/L | CH₃COOLi 1 mol/L | sample solution || membrane ||
145 internal filling solution; AgCl, Ag.

146 Potentiometric multiplexer (EMF 16 Interface, Lawson Labs Inc., Malvern, USA) was
147 used for the characterization of the sensors. The calibration curves of the electrodes
148 were examined by measuring the EMFs while increasing the concentration of the
149 APIs in steps of 0.5 log c in the range 10^{-5.5} – 10^{-1.5} mol/L (10^{-5.5} – 10⁻² mol/L for
150 acetylsalicylic acid). Repeatable sensor performances were recorded during at least
151 4 weeks.

152 For the quantitative analysis of APIs mixtures, the flow-through sensor array was
153 connected to the Sequential Injection Analysis (SIA) system providing the automated
154 operation and generation of API samples mixtures, thanks to the precise dosing and
155 mixing of volumes of stock solutions. The SIA system was formed by two
156 differentiated parts: the fluidic system and the measurement system [37,38], which
157 were wholly controlled by a PC using a virtual instrument developed in LabView,
158 where the other active elements were commanded through RS-232 communication
159 lines.

160 The fluidic system consisted of an automatic microburette (Crison 2030 microburette,
161 Crison, Spain) equipped with a 5-mL syringe (Hamilton, Switzerland), a holding coil
162 (5m×1mm i.d. PTFE tubing, Bioblock, France), a 8-way Hamilton MVP valve
163 (Hamilton, Switzerland) and a 7mL Perspex mixing cell (home built) with a magnetic
164 stirrer. The burette was connected to the multiport valve through the holding coil
165 placed in between, and fed through a carrier solution reservoir. In this way,
166 connection between the common port to the other ones (i.e. sample, standard stock
167 solutions, mixing chamber or sensor array port) was achieved by an electrical
168 rotation of the valve; all the elements being connected together using low pressure
169 liquid chromatography connectors.

170 The measurement system comprised the sensor array, a reference electrode
171 (miniaturised silver/silver chloride electrode with a double junction) and an 8-channel
172 signal conditioning circuit connected to the data acquisition analog inputs (National
173 Instruments NI6221 Multifunction DAQ, TX, USA).

174

175

176 2.4. Data analysis

177
178 Data analysis was performed in MatLab (The MathWorks, Inc., Natick, USA), Solo
179 (Eigenvector Research, Inc., Wenatchee, USA) and Origin (Microcal Software, Inc,
180 Northampton, USA) software. Chemical images of samples were processed using
181 Partial Least Squares (PLS) analysis in the case of models involving steady-state
182 signals, and 3-way PLS in the case of models based on dynamic responses of the
183 sensors. Analogously, ANN models were also built employing the dynamic
184 responses, but in this case requiring a preprocessing step aimed to the reduction of
185 signals complexity and dimensionality [39]. This was achieved by means of Discrete
186 Wavelet Transform (DWT) as feature extraction tool and Causal Index (CI) pruning of
187 the inputs to remove less-significant extracted coefficients that barely contribute to
188 the final model.

189

190

191 3. Results and discussion

192

193 The studied active pharmaceutical ingredients remain in neutral or anionic form in
194 solution, according to their pK_a values and pH conditions. Therefore, anion-sensitive
195 electrodes based on various ion-exchangers were applied for the quantitative
196 analysis of selected APIs. The electrodes constructed by incorporating
197 tetraalkylammonium and phosphonium salts in the PVC/o-NPOE membranes
198 exhibited almost theoretical values of the response slopes for acetylsalicylic acid (in
199 the range 10^{-4} – 10^{-2} mol/L), whereas significantly worse response sensitivities (<20
200 mV/decade) were measured for the weak acids: acetaminophen and ascorbic acid,
201 even in alkaline conditions. Comparable, poor sensitivity was observed in the case of
202 potentiometric sensors based on ionic liquid (1-decyl-3-methylimidazolium chloride)
203 towards all APIs, recorded in different pH conditions.

204 Additional cation-sensitive electrodes based on KTFPB in PVC/DOS membranes
205 were introduced to the sensor array, since the studied mixtures of APIs contained
206 also caffeine – a component commonly added to the pharmaceutical formulations
207 with anti-inflammatory drugs. However, due to the very low value of pK_a , the neutral
208 form of caffeine was predominant in solution under the studied pH range [25] and
209 thus the electrodes showed rather small and non-linear response to this component.

210

211 3.1. Quantitative analysis of APIs – PLS and 3-way PLS

212

213 The measurements of the sensor array signals were conducted in 80 sample
214 mixtures containing 3 APIs in different concentration ranges (1-20 mmol/L for
215 acetaminophen, 0.3-7 mmol/L for ascorbic acid and 1.4-8 mmol/L for acetylsalicylic
216 acid), prepared automatically by the Sequential Injection Analysis system (Figure 1)
217 [36,37]. The given concentration ranges were matched to the level of such APIs in
218 commercial drugs after their dissolution in water. Caffeine, added to each mixture
219 (0.13-1.3 mmol/L), was considered as an interferent (see Figure 1). The experiments
220 were performed in solutions at various pH in order to alter the structure of APIs and
221 sense individual components in particular pH conditions. Therefore, four carriers of
222 different pH: HCl solution (pH=1.8), lithium acetate solution (pH=5.0) and TRIS buffer
223 solution (pH=8.0 and pH=10.5) were used. In these solutions anionic species of
224 acetaminophen were present only at pH=10.5 (existed in small amounts at pH=8.0),
225 whereas acetylsalicylic acid and ascorbic acid remained in appreciable amount in
226 neutral form only at pH=1.8.

227 Data matrices involving the steady-state signals of the sensors after step introduction
228 of the samples were formed. Target matrices contained direct information on 3 APIs
229 concentrations (three-column calibration) or on 1 API concentration (single-column
230 calibration). Various variants of train data were considered (but in each case, 4:1 data
231 division was used to form the train and the test set, respectively):

- 232 • 4 PLS models based on data from single measurements in the given pH,
- 233 • 6 PLS models based on the combination of signals recorded in solutions of 2
234 values of pH,
- 235 • 4 PLS models based on the combination of signals recorded in solutions of 3
236 values of pH,
- 237 • 1 PLS model based on the combination of all signals recorded in all 4 values of
238 pH.

239 The PLS models were built with a number of Latent Variables (1 to 8 for PLS and 20
240 for 3-way PLS) enabling the minimization of the RMSE value. Their performance was
241 characterized after performing the linear fitting of the obtained data (PLS predicted
242 concentrations of API) versus the expected data (real concentrations of API). The
243 values of the slope (“a”), intercept (“b”) and determination coefficient (“R²”), were
244 calculated for the train and test samples, assuming that in the perfect case they
245 should reach values of 1, 0 and 1, respectively. It was found, that the data

246 dimensionality i.e. the combination of data from the experiments performed in various
247 pH conditions influenced the classification results. The best results were obtained for
248 the fusion of signals recorded in solutions of pH: 1.8, 8.0, 10.5 (see Table 2).
249 However, the concentration of only 2 APIs i.e. acetylsalicylic acid and ascorbic acid
250 was properly predicted. Even though acetaminophen should be in the anionic form in
251 the solution of highest pH value, the responses of the electrodes to this API did not
252 provide satisfactory result. Therefore, single-column calibration was attempted i.e.
253 separate PLS-1 models were created for each API, based on the fusion of signals
254 recorded in the same 3 values of pH. The same train and test data matrices were
255 used; however the target matrix was limited to one column – concentration of single
256 API. Unfortunately, the prediction of API concentration remained unsatisfactory,
257 especially for acetaminophen (Table 2).

258 In the next step, dynamic responses of the sensor array were applied in the train data
259 for multiway processing to enhance the amount of information gained by PLS model.
260 Whole responses (1800 data points per sensor) and the initial 30s of sensors
261 responses (first 300 data points per sensor) recorded in various combinations of pH
262 were used in multiway models. Better results were obtained in the case of 3-way PLS
263 analysis, but only for the train subset. Still, the results obtained for the test subsets
264 were not satisfactory, which was caused by poor prediction abilities of the 3-way PLS
265 models (see Table 3). However, quite better results were noticed when whole
266 dynamic response was considered (1800 points).

267

268 3.2. Quantitative analysis of APIs – DWT-ANN

269

270 As an alternative approach, the usage of ANNs was also considered. Compared with
271 PLS, ANNs are more flexible modelling methodologies, since both linear and non-
272 linear functions (or its combination) can be used in the processing units, thus being
273 especially suited when sensor responses show non-linear behaviors [39,40].
274 Moreover, allowing for more complex relationships between a high-dimensional
275 descriptor space and the given retention data, which might lead to better predictive
276 power of the resulting ANN model compared with other linear methods, although if
277 linearity exists, a proper behavior will be obtained also with the latter.

278 In this way, same approaches as previously described were also followed, i.e. the
279 usage of the steady state signal and building of models based on single- and multi-
280 pH values, with the same data division for the train and test subsets. However, none

281 of those approaches provided enough satisfactory results. The next step was then
282 the usage of the dynamic profile, as previously done with 3-way PLS. Nevertheless,
283 this was not as straightforward as in the previous case, as in here, before building the
284 ANN model, a preprocessing step devised for reducing the input dimensionality was
285 required.

286 For the dynamic treatment, a two-step feature extraction process was thus followed
287 to achieve the reduction of signals complexity and dimensionality. Firstly, the
288 response profile of each sensor was compressed employing DWT, and afterwards
289 ANNs were used as feature selection tool for variable selection [39]. In this way, the
290 dynamic potentiometric response (from 2.1s to 10.0s, comprising a total of 80 values;
291 see Figure 2) was compressed employing Daubechies wavelet mother function and a
292 second decomposition level down to 25 coefficients, without any loss of relevant
293 information. The obtained coefficients were then fed to an ANN model, which upon its
294 training, was used for the removal of the less-significant coefficients by Causal Index
295 (CI) pruning of the inputs [39,40]. This process was then iteratively repeated until
296 selection of an optimal subset of coefficients that allows doing the prediction task as
297 well as possible, with as few variables as possible. Lastly, the architecture of the ANN
298 model was optimized, as usual, by systematically fine-tuning its topology (i.e. training
299 algorithm, number of hidden layers, number of neurons, transfer functions, etc.) to
300 achieve the correct quantification of the desired compounds.

301 Subsequently, after pruning and optimization of the ANN model, comparison graphs
302 of predicted vs. expected scores, both for the train and test subsets, were built
303 (Figure 3) and the linear fitted regression parameters were calculated to easily check
304 the performance of the model (Table 4). As can be seen, acetylsalicylic acid (ASA)
305 can be perfectly modelled in all the cases with low difficulty, while counterbalancing
306 the changing concentrations of caffeine. On the other side, acetaminophen (PARA)
307 and ascorbic acid (ASC) modelling was also plausible, although obtained correlation
308 seem to be worst. Nevertheless, in all cases the obtained regression parameters
309 were close to the ideal ones; i.e. values of intercept close to 0, and slope and R^2
310 close to 1.

311
312
313
314

315 **4. Conclusions**

316

317 HPLC systems with UV detection are commonly applied for the routine analysis of
318 non-steroidal anti-inflammatory drugs (e.g. acetylsalicylic acid) in pharmaceutical
319 pain relievers. However, sophisticated instrumentation and skilled personnel are
320 essential to provide the proper chromatographic results. Therefore, a simpler
321 analytical approach based on sensor arrays systems would be beneficial due to the
322 automation and shortening of the analysis.

323 In this work, a flow-through sensor array of miniaturized potentiometric electrodes
324 containing only an ion-exchanger in polymeric membranes coupled with Sequential
325 Injection Analysis system was proposed for the quantitative analysis of selected
326 active pharmaceutical ingredients. Simple chemometric data processing involving
327 Partial Least Squares (PLS) analysis of the steady-state responses of the sensors as
328 well as multiway PLS fed by dynamic sensors responses enabled the determination
329 of acetylsalicylic acid and ascorbic acid in mixtures, while correcting any interference
330 derived from the presence of acetaminophen and caffeine. However, the extraction of
331 dynamic components of the transient response employing the Wavelet transform, the
332 removal of the less significant inputs by means of Causal Index pruning and training
333 of an Artificial Neural Network with the selected coefficients allowed the simultaneous
334 determination of the 3 APIs counterbalancing any interference caused by caffeine.

335

336 **Acknowledgements**

337 This work has been financially supported by National Science Centre within a
338 framework of OPUS project DEC-2013/09/B/ST4/00957 and by the project
339 LIDER/17/202/L-1/09/NCBiR/2010. Manel del Valle acknowledges the support from
340 the program ICREA Academia.

341

342 **References:**

- 343 1. E. Deconink, P.Y. Sacre, S. Baudewyns, P. Courselle, J. De Beer, *J. Pharm.*
344 *Biomed. Anal.* **2011**, *56*, 200-209.
- 345 2. J.T. Franeta, D. Agbaba, S. Eric, S. Pavkov, M. Aleksic, S. Vladimirov, *Il*
346 *Farmaco* **2002**, *57*, 709-713.
- 347 3. N. Moore, E. Van Ganse, J.-M. Le Parc, R. Wall, H. Schneid, M. Farhan, F.
348 Verrière, F. Pelen, *Clin. Drug Invest.* **1999**, *18(2)*, 89-98.
- 349 4. M. Espinosa Bosh, A.J. Ruiz Sanchez Rojas, C. Bosh Ojeda, *J. Pharm. Biomed.*
350 *Anal.* **2006**, *42*, 291-321.
- 351 5. M. Locatelli, L. Governatori, G. Carlucci, S. Genovese, A. Mollica, F. Epifano,
352 *Biomed. Chromatogr.* **2012**, *26*, 283-300.
- 353 6. M. Starek, *Talanta* **2001**, *85*, 8-27.
- 354 7. A.I. Olives, V. González-Ruiz, M.A. Martín, *Antiinflamm. Antiallergy Agents Med.*
355 *Chem.* **2012**, *11*, 65-95.
- 356 8. M.M. Abdulbari, M.Sh. Ihsan, *Int. J. Pharm. Pharm. Sci.* **2013**, *5*, 666-670.
- 357 9. H. Çağlar, E. Büyüktuncel, *Int. J. Pharm. Pharm. Sci.* **2014**, *6*, 421-428.
- 358 10. E. Dinc, D. Baleanu, *Il Farmaco* **2002**, *57*, 33-37.
- 359 11. E. Dinc, *Talanta* **1999**, *48*, 1145-1157.
- 360 12. E. Dinc, D. Baleanuc, G. Ioele, M. De Luca, G. Ragno, *J. Pharm. Biomed. Anal.*
361 **2008**, *48*, 1471-1475.
- 362 13. O.A. Donmez, A. Bozdogan, G. Kunt, Y. Div, *J. Anal. Chem.* **2010**, *65(1)*, 30-35.
- 363 14. V.D. Hoang, N.P. Nhung, H.Y. Aboul-Enein, *Curr. Pharm. Anal.* **2013**, *9*, 261-
364 277.
- 365 15. O.A. Farghaly, R.S. Abdel Hameed, Abd-Alhakeem H. Abu-Nawwas, *Int. J.*
366 *Pharm. Sci. Rev. Res.* **2014**, *25(2)*, 37-45.
- 367 16. A.M. Pisoschi, A. Pop, A.I. Serban, C. Fafaneata, *Electrochim. Acta* **2014**, *121*,
368 443-460.
- 369 17. A.A.J. Torriero, J.M. Luco, L. Sereno, J. Raba, *Talanta* **2004**, *62*, 247-254.
- 370 18. N. Adhoum, L. Monser, M. Toumi, K. Boujlel, *Anal. Chim. Acta* **2003**, *495*, 69-75.
- 371 19. B. Singhal, *World J. Chem.* **2011**, *6(2)*, 59-74.
- 372 20. E.G. Kulapina, O.V. Barinova, *Pharm. Chem. J.* **1997**, *31*, 667-672.
- 373 21. J. Lenik, C. Wardak, *Cent. Eur. J. Chem.* **2010**, *8(2)*, 382-391.
- 374 22. J. Lenik, B. Marczewska, C. Wardak, *Desalination* **2004**, *163*, 77-83.
- 375 23. J. Lenik, *Mater. Sci. Eng. C* **2013**, *33*, 311-316.
- 376 24. J. Lenik, *J. Anal. Chem.* **2012**, *67(6)*, 543-549.

- 377 25. T. Katsu, Y. Tsunamoto, N. Hanioka, K. Komagoe, K. Masuda, S. Narimatsu,
378 *Anal. Chim. Acta*, **2008**, 620, 50-54.
- 379 26. A.M. Pimenta, M.C.B.S.M. Montenegro, A.N. Araujo, J. Martinez Calatayud, J.
380 *Pharm. Biomed. Anal.* **2006**, 40, 16-34.
- 381 27. K. Woertz, C. Tissen, P. Kleinebudde, J. Breitreutz, *Int. J. Pharm.* **2011**, 417,
382 256-271.
- 383 28. P. Ciosek, W. Wróblewski, *Sensors* **2011**, 11, 4688-4701.
- 384 29. P. Ciosek, M. Wesoly, M. Zabadaj, Lisiecka J., Sołłohub B., Cal K., W.
385 Wróblewski, *Sens. Actuators B* **2015**, 207, 1087-1094.
- 386 30. M. Jańczyk, A. Kutyla, K. Sollohub, H. Wosicka, K. Cal, P. Ciosek,
387 *Bioelectrochemistry* **2010**, 80, 94-98.
- 388 31. T. Harada, T. Uchida, M. Yoshida, Y. Kobayashi, R. Narazaki, T. Ohwaka, *Chem.*
389 *Pharm. Bull.* **2010**, 58(8), 1009-1014.
- 390 32. A. Rudnitskaya, D. Kirsanov, Y. Blinova, E. Legin, B. Seleznev, D. Clapham, R.S.
391 Ives, K.A. Saunders, A. Legin, *Anal. Chim. Acta* **2013**, 770, 45-52.
- 392 33. M. Pein, C. Eckert, M. Preis, J. Breitreutz, *J. Pharm. Biomed. Anal.* **2013**, 83,
393 157-163.
- 394 34. K. Woertz, C. Tissen, P. Kleinebudde, J. Breitreutz, *J. Pharm. Biomed. Anal.*
395 **2011**, 55, 272-281.
- 396 35. E. Witkowska, A. Buczkowska, A. Zamojska, K.W. Szewczyk, P. Ciosek,
397 *Bioelectrochemistry* **2010**, 80, 87-93.
- 398 36. J. Markiewicz, J. Taff, B. Wysocki, W. Wróblewski, *Modular flow-through cell of*
399 *the ion-selective electrode for water quality monitoring, Polish Patent Application*
400 *PL 212005 B1*, **2012**.
- 401 37. A. Durán, M. Cortina, L. Velasco, J. Rodríguez, S. Alegret, M. del Valle, *Sensors*
402 **2005**, 6, 19-29.
- 403 38. A. Mimendia, J.M. Gutiérrez, L.J. Opalski, P. Ciosek, W. Wróblewski, M. del
404 Valle, *Talanta* **2010**, 82, 931-938.
- 405 39. X. Cetó, F. Céspedes, M. del Valle, *Microchim. Acta* 2013, 180, 319-330.
- 406 40. F. Despagne, D.L. Massart, *Analyst* **1998**, 123, 157R-178R.
- 407 41. M. Jańczyk, A. Kutyla-Olesiuk, X. Cetó, M. del Valle, P. Ciosek, W. Wróblewski,
408 *Sens. Actuators B* **2013**, 189, 179-186.
- 409

410 Table 1. Components used for the preparation of potentiometric electrodes.

411

Electrode type	Lipophilic salt	Plasticizer	Polymer	Internal filling/ Conditioning solution
1	3.5 wt% TDMAC	64.0 wt% o-NPOE	32.5 wt% PVC	0.01/0.001 mol/L NaCl
2	2.0 wt% TBHDPB	65.5 wt% o-NPOE	32.5 wt% PVC	
3	2.0 wt% IL	65.5 wt% o-NPOE	32.5 wt% PVC	
4	1.0 wt% KTFPB	66.0 wt% DOS	33.0 wt% PVC	

412

413 Table 2. Parameters of linear fitting of real and PLS-predicted concentration of APIs.

414

		Three-column calibration			Single-column calibration		
		acetaminophen	ascorbic acid	acetylsalicylic acid	acetaminophen	ascorbic acid	acetylsalicylic acid
TRAIN	a	0.72±0.06	0.84±0.05	0.98±0.02	0.22±0.05	0.68±0.06	0.94±0.03
	b	0.00±0.00	0.00±0.00	0.00±0.00	0.01±0.00	0.00±0.00	0.00±0.00
	R ²	0.72	0.84	0.98	0.22	0.68	0.94
TEST	a	0.52±0.28	0.60±0.20	0.96±0.03	0.11±0.08	0.58±0.19	0.94±0.04
	b	0.01±0.00	0.00±0.00	0.00±0.00	0.01±0.00	0.00±0.00	0.00±0.00
	R ²	0.19	0.41	0.98	0.12	0.40	0.98

415

416 Table 3. Parameters of linear fitting of real and 3-way PLS-predicted concentration of
 417 APIs.
 418

		Calibration based on 1800 data points			Calibration based on 300 data points		
		acetaminophen	ascorbic acid	acetylsalicylic acid	acetaminophen	ascorbic acid	acetylsalicylic acid
TRAIN	a	0.86±0.04	0.75±0.08	0.98±0.08	0.69±0.06	0.65±0.06	0.98±0.01
	b	0.00±0.00	0.00±0.00	0.00±0.00	0.00±0.00	0.00±0.00	0.00±0.00
	R ²	0.96	0.92	0.99	0.91	0.89	0.99
TEST	a	0.31±0.18	0.80±0.19	0.97±0.05	0.60±0.12	0.41±0.10	0.97±0.03
	b	0.00±0.00	0.00±0.00	0.00±0.00	0.00±0.00	0.00±0.00	0.00±0.00
	R ²	0.00	0.45	0.96	0.62	0.49	0.98

419

420 Table 4. Parameters of linear fitting of real and DWT-CI-ANN-predicted concentration of
 421 APIs.
 422

		acetaminophen	ascorbic acid	acetylsalicylic acid
TRAIN	a	0.96±0.02	0.96±0.01	0.98±0.01
	b	0.37±0.17	0.13±0.04	0.084±0.057
	R ²	0.99	1.00	1.00
TEST	a	0.98±0.27	1.00±0.35	1.03±0.09
	b	-0.42±3.00	0.13±1.23	-0.11±0.39
	R ²	0.82	0.73	0.98

423


424 **Figure captions:**

425 Figure 1. Random distribution of concentrations of the four species for the (●) train
426 and (★) test samples prepared automatically by the SIA system.
427 Acetaminophen (PARA), ascorbic acid (ASC) and acetylsalicylic acid
428 (ASA) are plotted in x,y,z coordinates respectively, whereas caffeine (KOF)
429 is plotted as a color-scale in the scatter plot.

430 Figure 2. Exemplary dynamic responses of the electrode based on TDMAC (PVC/o-
431 NPOE membrane) recorded in arbitrary mixture of APIs (1.4 mmol/L
432 acetaminophen, 0.91 mmol/L ascorbic acid, 6.6 mmol/L acetylsalicylic acid
433 and 0.68 mmol/L caffeine) in 4 carriers at various pH values


434 Figure 3. Model performances characterized after linear fitting of the real
435 concentrations of APIs to the predicted data by the DWT-CI-ANN model.
436 Train set (●, solid line), test set (○, dotted line) and theoretical diagonal line
437 (dashed line).

438






439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454

Figure 1.



455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472

Figure 2.



473
474
475
476
477
478
479
480
481
482
483

Figure 3